echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Janssen/Legendary Bio's CAR-T Therapy Receives FDA Priority Review Eligibility for Treatment of Multiple Myeloma

    Janssen/Legendary Bio's CAR-T Therapy Receives FDA Priority Review Eligibility for Treatment of Multiple Myeloma

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Legend Bio announced that the U.


    Legend Bio announced that the U.


    ▲Structural diagram of Cilta-cel (also known as JNJ-4528/LCAR-B38M) (Image source: Legendary Biology official website)

    Cilta-cel's regulatory submission is based on the results of the critical 1b/2 CARTITUDE-1 study.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.